Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community

The aim of this study was to examine the relation of galectin-3 (Gal-3), a marker of cardiac fibrosis, with incident heart failure (HF) in the community. Gal-3 is an emerging prognostic biomarker in HF, and experimental studies suggest that Gal-3 is an important mediator of cardiac fibrosis. Whether...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology Vol. 60; no. 14; p. 1249
Main Authors: Ho, Jennifer E, Liu, Chunyu, Lyass, Asya, Courchesne, Paul, Pencina, Michael J, Vasan, Ramachandran S, Larson, Martin G, Levy, Daniel
Format: Journal Article
Language:English
Published: United States 02.10.2012
Subjects:
Aged
Biomarkers - blood
Cohort Studies
Cross-Sectional Studies
Female
Fibrosis - blood
Galectin 3 - blood
Heart Failure - blood
Heart Failure - mortality
Heart Ventricles - physiopathology
Humans
Incidence
Longitudinal Studies
Male
Middle Aged
Myocardium - pathology
Natriuretic Peptide, Brain - blood
Prognosis
Prospective Studies
Risk Factors
Stroke Volume
ISSN:1558-3597, 1558-3597
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The aim of this study was to examine the relation of galectin-3 (Gal-3), a marker of cardiac fibrosis, with incident heart failure (HF) in the community. Gal-3 is an emerging prognostic biomarker in HF, and experimental studies suggest that Gal-3 is an important mediator of cardiac fibrosis. Whether elevated Gal-3 concentrations precede the development of HF is unknown. Gal-3 concentrations were measured in 3,353 participants in the Framingham Offspring Cohort (mean age 59 years; 53% women). The relation of Gal-3 to incident HF was assessed using proportional hazards regression. Gal-3 was associated with increased left ventricular mass in age-adjusted and sex-adjusted analyses (p = 0.001); this association was attenuated in multivariate analyses (p = 0.06). A total of 166 participants developed incident HF and 468 died during a mean follow-up period of 11.2 years. Gal-3 was associated with risk for incident HF (hazard ratio [HR]: 1.28 per 1 SD increase in log Gal-3; 95% confidence interval [CI]: 1.14 to 1.43; p < 0.0001) and remained significant after adjustment for clinical variables and B-type natriuretic peptide (HR: 1.23; 95% CI: 1.04 to 1.47; p = 0.02). Gal-3 was also associated with risk for all-cause mortality (multivariable-adjusted HR: 1.15; 95% CI: 1.04 to 1.28; p = 0.01). The addition of Gal-3 to clinical factors resulted in negligible changes to the C-statistic and minor improvements in net reclassification improvement. Higher concentration of Gal-3, a marker of cardiac fibrosis, is associated with increased risk for incident HF and mortality. Future studies evaluating the role of Gal-3 in cardiac remodeling may provide further insights into the role of Gal-3 in the pathophysiology of HF.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1558-3597
1558-3597
DOI:10.1016/j.jacc.2012.04.053